AZD0780
- Generic Name
- AZD0780
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
Phase 2
Recruiting
- Conditions
- Dyslipidaemia
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06834932
- Locations
- ππ°
Research Site, Hong Kong, Hong Kong
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
Phase 1
Recruiting
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06742853
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Phase 2
Completed
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 202
- Registration Number
- NCT06692764
- Locations
- πΊπΈ
Research Site, Paris, Texas, United States
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
Phase 1
Completed
- Conditions
- Dyslipidaemia
- Interventions
- Drug: Ethinyl estradiol/levonorgestrel
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT06671405
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06592482
- Locations
- πΊπΈ
Research Site, Saint Paul, Minnesota, United States
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06576765
- Locations
- πΊπΈ
Research Site, San Antonio, Texas, United States
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 428
- Registration Number
- NCT06173570
- Locations
- πͺπΈ
Research Site, Sevilla, Spain
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05787002
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 183
- Registration Number
- NCT05384262
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath